• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对早老性阿尔茨海默病患者进行GM1神经节苷脂的肠胃外给药。

Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.

作者信息

Svennerholm L, Gottfries C G, Blennow K, Fredman P, Karlsson I, Månsson J E, Toffano G, Wallin A

机构信息

Department of Psychiatry and Neurochemistry, Gothenburg University, Sweden.

出版信息

Acta Neurol Scand. 1990 Jan;81(1):48-53. doi: 10.1111/j.1600-0404.1990.tb00930.x.

DOI:10.1111/j.1600-0404.1990.tb00930.x
PMID:2330815
Abstract

The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 +/- 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 mumol/l were found in 3 patients. The elimination half-life from serum was 60-75 h.

摘要

对16例(平均年龄64±5岁)阿尔茨海默病患者进行了GM1神经节苷脂的药代动力学参数研究。该神经节苷脂通过肌肉注射和皮下注射给药。48 - 72小时后达到GM1血药浓度峰值,皮下给药途径导致血药浓度最高,但个体差异相对较大。当每天给予100mg GM1神经节苷脂,持续一周时,3例患者的血清最大值为15至20μmol/L。血清消除半衰期为60 - 75小时。

相似文献

1
Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.对早老性阿尔茨海默病患者进行GM1神经节苷脂的肠胃外给药。
Acta Neurol Scand. 1990 Jan;81(1):48-53. doi: 10.1111/j.1600-0404.1990.tb00930.x.
2
Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers.神经节苷脂GM1对健康志愿者静脉注射和肌肉注射后的多剂量药代动力学
Clin Pharmacol Ther. 1991 Aug;50(2):141-9. doi: 10.1038/clpt.1991.118.
3
Pharmacokinetics of GM1 ganglioside following parenteral administration.肠胃外给药后GM1神经节苷脂的药代动力学
J Pharm Pharmacol. 1990 Oct;42(10):708-11. doi: 10.1111/j.2042-7158.1990.tb06564.x.
4
Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.向早老性阿尔茨海默病患者脑室内注射神经节苷脂GM1。
Dement Geriatr Cogn Disord. 1997 Jan-Feb;8(1):26-33. doi: 10.1159/000106597.
5
Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms.两例因外源性GM1导致急性抗GM1抗体升高但无神经症状的病例。
J Neuroimmunol. 1994 Aug;53(1):109-13. doi: 10.1016/0165-5728(94)90070-1.
6
Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme.阿尔茨海默病——GM1神经节苷脂持续脑室内治疗及系统性激活方案的效果
Dement Geriatr Cogn Disord. 2002;14(3):128-36. doi: 10.1159/000063604.
7
Trial of ganglioside GM1 in acute stroke.神经节苷脂GM1治疗急性中风的试验。
J Neurol Neurosurg Psychiatry. 1988 Sep;51(9):1213-4. doi: 10.1136/jnnp.51.9.1213.
8
Disposition of exogenous tritium-labelled GM1lactone in the rat.外源性氚标记的GM1内酯在大鼠体内的分布
Neurochem Int. 1992 Apr;20(3):359-64. doi: 10.1016/0197-0186(92)90050-2.
9
Ganglioside GM1 in acute ischemic stroke. The SASS Trial.急性缺血性卒中中的神经节苷脂GM1。SASS试验。
Stroke. 1994 Jun;25(6):1141-8. doi: 10.1161/01.str.25.6.1141.
10
Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease.神经节苷脂——一种治疗中风和阿尔茨海默病的新型药物。
Life Sci. 1994;55(25-26):2125-34. doi: 10.1016/0024-3205(94)00393-9.

引用本文的文献

1
Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition.神经节苷脂与神经退行性疾病的治疗:悠久的意大利传统。
Biomedicines. 2022 Feb 2;10(2):363. doi: 10.3390/biomedicines10020363.
2
Glycosphingolipids.糖脂
Adv Exp Med Biol. 2021;1325:61-102. doi: 10.1007/978-3-030-70115-4_3.
3
GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular Route.GM1 寡糖通过细胞旁途径在体外穿过人血脑屏障。
Int J Mol Sci. 2020 Apr 19;21(8):2858. doi: 10.3390/ijms21082858.
4
GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.神经节苷脂 GM1 是维持哺乳动物神经元功能、避免神经退行性变的关键因素。
Int J Mol Sci. 2020 Jan 29;21(3):868. doi: 10.3390/ijms21030868.
5
Intracerebroventricular Infusion of Gangliosides Augments the Adult Neural Stem Cell Pool in Mouse Brain.脑室内注射神经节苷脂可增加成年小鼠脑内神经干细胞池。
ASN Neuro. 2019 Jan-Dec;11:1759091419884859. doi: 10.1177/1759091419884859.
6
Gangliosides: Treatment Avenues in Neurodegenerative Disease.神经节苷脂:神经退行性疾病的治疗途径
Front Neurol. 2019 Aug 6;10:859. doi: 10.3389/fneur.2019.00859. eCollection 2019.
7
A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.GM1 神经节苷脂治疗帕金森病患者的随机、对照、延迟启动试验。
J Neurol Sci. 2013 Jan 15;324(1-2):140-8. doi: 10.1016/j.jns.2012.10.024. Epub 2012 Nov 28.
8
Cognitive enhancement therapy for Alzheimer's disease. The way forward.阿尔茨海默病的认知增强疗法。前进的道路。
Drugs. 1997 May;53(5):752-68. doi: 10.2165/00003495-199753050-00003.
9
Advances in the pharmacotherapy of Alzheimer's disease.阿尔茨海默病药物治疗的进展
Eur Arch Psychiatry Clin Neurosci. 1994;244(5):261-71. doi: 10.1007/BF02190379.
10
Clinical pharmacokinetics of drugs for Alzheimer's disease.用于治疗阿尔茨海默病药物的临床药代动力学
Clin Pharmacokinet. 1995 Aug;29(2):110-29. doi: 10.2165/00003088-199529020-00005.